公认风湿性心脏病(尤其是二尖瓣狭窄)伴心房颤动(房颤)易并发栓塞,因而需进行抗凝治疗预防栓塞。至于非风湿性房颤病人,虽然也有颇高的体循环栓塞与中风危险,是否也需抗凝冶疗预防,则尚无定论。血管病病人非随机口服抗凝剂治疗与随机抗凝和抗血小板治疗试验降低栓塞发生的结果,以及小剂量华法令治疗被证实具高度安全性,促进了探讨非风湿性房颤抗凝和抗血小板治疗的多个随机临床试验的进行,有些已完成,以下综述非风湿性房颤的抗凝治疗。患病率与发生率研究人群的年龄和健康状况不同可明显影响房颤的患病率。健康人群中患病率为5/122043(美国健康全军飞行员,男,15～50岁),0.4％(16岁以上成人),与 It is recognized that rheumatic heart disease (especially mitral stenosis) is associated with atrial fibrillation (atrial fibrillation) complicated by embolism, which requires anticoagulant therapy to prevent embolism. As for non-rheumatic atrial fibrillation patients, although there is also a high risk of systemic embolism and stroke, whether anticoagulation therapy is also required, there is no conclusion. Non-randomized oral anticoagulant therapy in patients with vascular disease and randomized anticoagulant and antiplatelet therapy trials to reduce the incidence of embolization, as well as low-dose warfarin therapy have been shown to be highly safe and to promote the study of non-rheumatic atrial fibrillation and anti-coagulation Several randomized clinical trials of platelet therapy have been completed, and the following is a review of anticoagulant therapy for non-rheumatic atrial fibrillation. Prevalence and Incidence Rates The prevalence of atrial fibrillation can be significantly affected by differences in the age and health status of the population. The prevalence rate in healthy population was 5/122043 (US Healthy Whole Army Pilots, male, 15 to 50 years old), 0.4% (adults over 16 years old), and